LONDON, UK, Monday 28 September 2015, 07:00 GMT+1 – Norgine B.V. today announced that it has sponsored a new campaign led by the European Liver Patients Association (ELPA). Time to DeLiver: Optimising Patient Outcomes in Hepatic Encephalopathy, Abstract P38 was presented at the weekend at the EASL Special Conference, 25-27 September, Glasgow.1
The campaign 'Time to DeLiver' aims to drive greater awareness of hepatic encephalopathy and its impact on patients and their families, health systems and policy makers, and to improve identification and management of this debilitating condition.[i] The full campaign report 'Time To DeLiver: Getting a Grip on Hepatic Encephalopathy' will be launched on Monday 12 October at 18:30 at the European Parliament, Brussels.
Hepatic encephalopathy is a potentially life-threatening neuropsychiatric condition associated with liver disease. Hepatic encephalopathy affects approximately 200,000 people in Europe who suffer from advanced chronic liver disease.[ii],[iii] Hepatic encephalopathy remains underdiagnosed and under-treated, resulting in poor quality of life for patients and high burden on their carers, families and society.
To register to attend the launch of the report on Monday 12 October 2015 please contact: [email protected]

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.